Purpose: To analyze visual acuity at 3 months after treatment.
Method: This prospective, randomised, interven- tional study included thirty two patients aged 5- 12 years of age with unilateral amblyopia or bilat- eral amblyopia. One group (A) of sixteen patients were prescribed occlusion therapy and the other group (B) received 1000 mg per day of omega fatty acids along with occlusion for a period of three months. Follow-up assessments included best cor- rected visual acuity (BCVA) (both distance and near) and stereoacuity measurements at 1 week and end of three months.
Results: mean age of the patients was 8.68
1.55 years. The mean baseline visual acuity for dis- tance was 0.85 0.071 Log MAR e.q. for Group A and 0.81 0.073 Log MAR e.q. for Group B. At the end of therapy, the mean visual acuity was 0.48
0.91 Log MAR e.q. and 0.40 0.20 Log MAR
e.q. for Group A and B respectively. Within the Groups there was statistically signiﬁcant improve- ment in vision Group A (P value-0.0008) and Group B (P value-0.0001). When both groups were com- pared results were insigniﬁcant (P value-0.373). Conclusion: Omega fatty acids improves visual acu- ity in patients with amblyopia and maintains improved visual acuity but there is no additional beneﬁt when compared to patching alone . This study encourages further research on this subject.
IRREVERSIBLE LENALIDOMIDE RELATED OPTIC NEUROPATHY IN A PATIENT WITH CHRONIC MYELOID LEUKAEMIA
A cost-effectiveness analysis of AcrySof IQ vivity intraocular lens from private health fund perspective in Australia
Efficacy and safety of intravitreal pegcetacoplan in geographic atrophy: Results from the phase 3 DERBY and OAKS trials